ADVFN - Advanced Financial Network.
HOME» NASDAQ » H » HALO Stock Price » HALO Stock News

Halozyme Therapeutics Share News

 Halozyme Therapeutics (mm) Stock Price
HALO Stock Price
 Halozyme Therapeutics (mm) Stock Chart
HALO Stock Chart
 Halozyme Therapeutics (mm) Stock News
HALO Stock News
 Halozyme Therapeutics (mm) Company Information
HALO Company Information
 Halozyme Therapeutics (mm) Stock Trades
HALO Stock Trades

Amylin, MannKind Shares Rise On Diabetes Data Releases

DOW JONES NEWSWIRES Drug companies unleashed a glut of research about diabetes treatments Friday, including data about the popular Byetta treatment and longer-acting versions of it, which boosted Amylin Pharmaceuticals Inc.'s (AMLN) shares after hours, as well as encouraging statements about an inhaled-insulin treatment from MannKind Corp. (MNKD). The releases came as the American Diabetes Association's annual scientific meeting kicked off in San Diego. Amylin, Eli Lilly & Co. (LLY) and Alkermes Inc. (ALKS) released two reports about Bydureon, a once-weekly version of the already-approved diabetes drug Byetta. The Food and Drug Administration declined to approve Bydureon in October, substantially delaying a widely expected approval. Friday, results from one Bydureon study suggested the treatment didn't slow the heart rate in patients with type-2 diabetes. Other Bydureon studies showed that type-2 patients showed improvement in glycemic control and lost weight over the course of several years, the companies said. The three companies also released data on an investigational, once-monthly injectable suspension formulation of the drug. They said a midstage study indicated "substantial improvement" in glycemic control with modest weight loss. Regarding Byetta, Amylin and Lilly reported that a retrospective analysis of more than 778,000 patients showed adding Byetta injection to pre-existing diabetes treatment regimens was associated with reduced chances for heart failure. On its own, Amylin said a study of another already approved diabetes drug, Symlin, showed the treatment helped reduce the average level of blood sugar, insulin use and body weight in type-1 patients who used insulin pumps. Amylin shares rose 5.7% to $12.50 after hours. Alkermes shares rose 0.4% to $17.37, and Lilly's weren't active. MannKind reported two separate sets of findings about its inhaled insulin treatment, Afrezza. The company has been trying to win FDA approval for the treatment, but investors haven't been impressed by the rate of progress. Friday, it said two studies "further substantiate" that treatment with Afrezza doesn't cause excess cardiovascular events, like heart attack or artery disease, in type-1 or type-2 patients. It also said a study showed type-1 patients who received Afrezza combined with basal insulin had a more positive view about insulin therapy than those who used a standard therapy with basal insulin. MannKind shares were up 9% at $4.35 after hours. Through the close, the stock has declined 51% so far this year. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Halozyme Therapeutics (HALO)
DateTimeHeadline
02/04/201616:20:37Statement of Changes in Beneficial Ownership (4)
02/04/201616:18:27Statement of Changes in Beneficial Ownership (4)
02/01/201616:30:00Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results...
01/26/201616:16:52Current Report Filing (8-k)
01/26/201616:05:00Halozyme Announces Closing Of $150 Million Royalty-Backed Debt...
01/26/201614:14:18Amended Statement of Ownership (sc 13g/a)
01/26/201611:20:19Amended Statement of Ownership (sc 13g/a)
01/21/201608:35:00Halozyme Announces First Clinical Dosing Of Adalimumab (Humira...
01/13/201608:31:54Current Report Filing (8-k)
01/12/201616:05:59Amended Statement of Changes in Beneficial Ownership (4/a)
01/11/201608:46:59Current Report Filing (8-k)
01/11/201608:30:00Halozyme Provides Key Program Updates, 2016 Financial Guidance...
01/07/201617:26:44Statement of Changes in Beneficial Ownership (4)
01/07/201617:26:44Statement of Changes in Beneficial Ownership (4)
01/05/201616:30:00Halozyme Therapeutics To Present At The 34th Annual J.P. Morgan...
01/04/201608:46:28Current Report Filing (8-k)
01/04/201608:30:00Halozyme Enters Into Agreement For $150 Million Non-Dilutive...
12/21/201508:30:00Halozyme Enters Into Global Collaboration And Licensing Agreement...
12/09/201508:30:00Halozyme Therapeutics and Eisai to present data evaluating the...
12/05/201516:04:03Why Halozyme Therapeutics Inc. Jumped 13% in November

Halozyme Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad